126 related articles for article (PubMed ID: 29772712)
1. Inhibition of Human Immunodeficiency Virus Type 1 Entry by a Keggin Polyoxometalate.
Wang X; Wang J; Zhang W; Li B; Zhu Y; Hu Q; Yang Y; Zhang X; Yan H; Zeng Y
Viruses; 2018 May; 10(5):. PubMed ID: 29772712
[TBL] [Abstract][Full Text] [Related]
2. ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation.
Wang H; Qi Z; Guo A; Mao Q; Lu H; An X; Xia C; Li X; Debnath AK; Wu S; Liu S; Jiang S
Antimicrob Agents Chemother; 2009 Dec; 53(12):4987-98. PubMed ID: 19786602
[TBL] [Abstract][Full Text] [Related]
3. HbAHP-25, an In-Silico Designed Peptide, Inhibits HIV-1 Entry by Blocking gp120 Binding to CD4 Receptor.
Bashir T; Patgaonkar M; Kumar SC; Pasi A; Reddy KV
PLoS One; 2015; 10(4):e0124839. PubMed ID: 25915507
[TBL] [Abstract][Full Text] [Related]
4. Role for the disulfide-bonded region of human immunodeficiency virus type 1 gp41 in receptor-triggered activation of membrane fusion function.
Bellamy-McIntyre AK; Bär S; Ludlow L; Drummer HE; Poumbourios P
Biochem Biophys Res Commun; 2010 Apr; 394(4):904-8. PubMed ID: 20230797
[TBL] [Abstract][Full Text] [Related]
5. Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4.
Yang QE; Stephen AG; Adelsberger JW; Roberts PE; Zhu W; Currens MJ; Feng Y; Crise BJ; Gorelick RJ; Rein AR; Fisher RJ; Shoemaker RH; Sei S
J Virol; 2005 May; 79(10):6122-33. PubMed ID: 15857997
[TBL] [Abstract][Full Text] [Related]
6. A peptide inhibitor of human immunodeficiency virus infection binds to novel human cell surface polypeptides.
Henderson LA; Qureshi MN
J Biol Chem; 1993 Jul; 268(20):15291-7. PubMed ID: 8325899
[TBL] [Abstract][Full Text] [Related]
7. An inducible HIV type 1 gp41 HR-2 peptide-binding site on HIV type 1 envelope gp120.
Alam SM; Paleos CA; Liao HX; Scearce R; Robinson J; Haynes BF
AIDS Res Hum Retroviruses; 2004 Aug; 20(8):836-45. PubMed ID: 15320988
[TBL] [Abstract][Full Text] [Related]
8. Amphotericin B derivative blocks human immunodeficiency virus type 1 entry after CD4 binding: effect on virus-cell fusion but not on cell-cell fusion.
Pleskoff O; Seman M; Alizon M
J Virol; 1995 Jan; 69(1):570-4. PubMed ID: 7983757
[TBL] [Abstract][Full Text] [Related]
9. Progress in targeting HIV-1 entry.
Ryser HJ; Flückiger R
Drug Discov Today; 2005 Aug; 10(16):1085-94. PubMed ID: 16182193
[TBL] [Abstract][Full Text] [Related]
10. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
Platt EJ; Durnin JP; Kabat D
J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435
[TBL] [Abstract][Full Text] [Related]
11. The Cellular Thioredoxin-1/Thioredoxin Reductase-1 Driven Oxidoreduction Represents a Chemotherapeutic Target for HIV-1 Entry Inhibition.
Reiser K; Mathys L; Curbo S; Pannecouque C; Noppen S; Liekens S; Engman L; Lundberg M; Balzarini J; Karlsson A
PLoS One; 2016; 11(1):e0147773. PubMed ID: 26816344
[TBL] [Abstract][Full Text] [Related]
12. Broad-spectrum anti-human immunodeficiency virus (HIV) potential of a peptide HIV type 1 entry inhibitor.
Cocklin S; Gopi H; Querido B; Nimmagadda M; Kuriakose S; Cicala C; Ajith S; Baxter S; Arthos J; Martín-García J; Chaiken IM
J Virol; 2007 Apr; 81(7):3645-8. PubMed ID: 17251295
[TBL] [Abstract][Full Text] [Related]
13. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.
Jiang S; Lu H; Liu S; Zhao Q; He Y; Debnath AK
Antimicrob Agents Chemother; 2004 Nov; 48(11):4349-59. PubMed ID: 15504864
[TBL] [Abstract][Full Text] [Related]
14. Role of envelope processing and gp41 membrane spanning domain in the formation of human immunodeficiency virus type 1 (HIV-1) fusion-competent envelope glycoprotein complex.
Welman M; Lemay G; Cohen EA
Virus Res; 2007 Mar; 124(1-2):103-12. PubMed ID: 17129629
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, antiviral activity and resistance of a novel small molecule HIV-1 entry inhibitor.
Curreli F; Haque K; Xie L; Qiu Q; Xu J; Yong W; Tong X; Debnath AK
Bioorg Med Chem; 2015 Dec; 23(24):7618-28. PubMed ID: 26602829
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded.
Quitadamo B; Peters PJ; Repik A; O'Connell O; Mou Z; Koch M; Somasundaran M; Brody R; Luzuriaga K; Wallace A; Wang S; Lu S; McCauley S; Luban J; Duenas-Decamp M; Gonzalez-Perez MP; Clapham PR
J Virol; 2018 Jan; 92(2):. PubMed ID: 29118121
[TBL] [Abstract][Full Text] [Related]
17. Functional analysis of the disulfide-bonded loop/chain reversal region of human immunodeficiency virus type 1 gp41 reveals a critical role in gp120-gp41 association.
Maerz AL; Drummer HE; Wilson KA; Poumbourios P
J Virol; 2001 Jul; 75(14):6635-44. PubMed ID: 11413331
[TBL] [Abstract][Full Text] [Related]
18. Tryptophan dendrimers that inhibit HIV replication, prevent virus entry and bind to the HIV envelope glycoproteins gp120 and gp41.
Rivero-Buceta E; Doyagüez EG; Colomer I; Quesada E; Mathys L; Noppen S; Liekens S; Camarasa MJ; Pérez-Pérez MJ; Balzarini J; San-Félix A
Eur J Med Chem; 2015 Dec; 106():34-43. PubMed ID: 26513643
[TBL] [Abstract][Full Text] [Related]
19. Broad spectrum anti-RNA virus activities of titanium and vanadium substituted polyoxotungstates.
Shigeta S; Mori S; Kodama E; Kodama J; Takahashi K; Yamase T
Antiviral Res; 2003 May; 58(3):265-71. PubMed ID: 12767474
[TBL] [Abstract][Full Text] [Related]
20. Potent strategy to inhibit HIV-1 by binding both gp120 and gp41.
Kagiampakis I; Gharibi A; Mankowski MK; Snyder BA; Ptak RG; Alatas K; LiWang PJ
Antimicrob Agents Chemother; 2011 Jan; 55(1):264-75. PubMed ID: 20956603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
